Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.68 | N/A | +5.16% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.68 | N/A | +5.16% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about the current market conditions affecting their operations. They emphasized their commitment to pipeline development.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite current challenges.
Nektar Therapeutics reported a wider-than-expected loss per share but did not disclose revenue figures. The stock reacted negatively, declining by 0.86%, likely due to the lack of revenue guidance and management's cautious tone regarding future prospects. Investors may be concerned about the company's ability to navigate current challenges without clear financial direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SUNCOR ENERGY INC NE
May 3, 2021